As you might know, Oscar Health, Inc. (NYSE:OSCR) recently reported its annual numbers. Revenue hit US$5.9b in line with forecasts, although the company reported a statutory loss per share of US$1.22 that was somewhat smaller than the analyst expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analyst is forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analyst has changed their mind on Oscar Health after the latest results.

Taking into account the latest results, the most recent consensus for Oscar Health from sole analyst is for revenues of US$8.39b in 2024. If met, it would imply a major 43% increase on its revenue over the past 12 months. Per-share statutory losses are expected to explode, reaching US$0.025 per share. Before this earnings report, the analyst had been forecasting revenues of US$8.39b and earnings per share (EPS) of US$0.04 in 2024. While the analyst has made no real change to their revenue estimates, we can see that the consensus is now modelling a loss next year - a clear dip in sentiment compared to the previous outlook of a profit.

Despite expectations of heavier losses next year,the analyst has lifted their price target 17% to US$18.67, perhaps implying these losses are not expected to be recurring over the long term.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Oscar Health's revenue growth is expected to slow, with the forecast 43% annualised growth rate until the end of 2024 being well below the historical 63% p.a. growth over the last three years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 5.9% per year. So it's pretty clear that, while Oscar Health's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.

The Bottom Line

The biggest low-light for us was that the forecasts for Oscar Health dropped from profits to a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analyst believes the intrinsic value of the business is likely to improve over time.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2025, which can be seen for free on our platform here.

Before you take the next step you should know about the 2 warning signs for Oscar Health that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.